|By PR Newswire||
|August 22, 2014 09:10 AM EDT||
NEW YORK, August 22, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Aon plc (NYSE: AON), U.S. Bancorp (NYSE: USB), Ally Financial Inc. (NYSE: ALLY), Teva Pharmaceutical Industries Limited (NYSE: TEVA) and Pharmacyclics Inc. (NYSE: PCYC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5918-100free.
Aon plc Research Reports
On August 18, 2014, Aon Hewitt, the global talent, retirement and health solutions business of Aon plc, said that defined benefit pension schemes should divert sponsor contributions into alternative financing strategies as they climb towards healthier funding status, with many of the schemes over 100% funded. Aon Hewitt's recent survey of 86 clients with recently completed funding valuations showed that 30% of them were substantially above 100% funded, while 42% of them were around 100% funded on a best estimate basis. "As they become less keen on paying in cash we are already starting to see more companies considering alternative ways of providing that security, including escrow, charges over assets, letters of credit, surety bonds and other mechanisms. As ever with pensions, there is no one-size-fits-all but we believe that alternative financing solutions are an option that every DB pension scheme should be considering as part of their strategy to reach pensions stability," said Lynda Whitney, Partner at Aon Hewitt. The full research reports on Aon are available to download free of charge at:
U.S. Bancorp Research Reports
On August 11, 2014, U.S. Bank, a subsidiary of U.S. Bancorp, announced that it closed on several tax-credit financing packages of more than $77 million with Dominium, a Minneapolis-based apartment development and management company. According to the U.S. Bank, Dominium will use the funds to develop the century-old Arcade Building into a mixed-use space for university classes and 282 market rate and affordable-housing apartments. The U.S. Bank said it raised $77 million through its investments in federal New Markets Tax Credits, federal and state historic tax credits and a separate investment arranged from federal low-income housing tax credits. "Tremendous persistence, commitment and a deep desire to support the emergence of downtown St. Louis as an arts and innovation community kept our team motivated to make this development come to fruition," said Zack Boyers, Chairman and CEO of U.S. Bancorp Community Development Corporation (USBCDC). The full research reports on U.S. Bancorp are available to download free of charge at:
Ally Financial Inc. Research Reports
On August 19, 2014, Ally Financial Inc (Ally Financial) reported that its direct banking subsidiary Ally Bank topped the ranking in a recent study of the websites for 13 of the nation's top banks, according to Change Sciences® Group. The Company stated that the Consumer Bank Website User Experience Study rated each company's website for usability, engagement and conversion. Ally Bank said that Change Sciences recognized its website for recent page refinements, the top-level navigation of its website, integrating tools into product pages, providing an interactive calculator to estimate interest earnings, and a simple layout for product reviews. Ally Bank informed that it recently completed a significant redesign of its deposit product pages, leveraging consumer feedback to ensure site optimization. The full research reports on Ally Financial are available to download free of charge at:
Teva Pharmaceutical Industries Limited Research Reports
On August 19, 2014, the stock of Teva Pharmaceuticals Industries Limited (Teva) gained 0.76% to end the trading session at $52.79. Shares in Teva opened at $52.05, and fluctuated in the range of $52.04 - $52.84. A total of 3.44 million shares were traded during the session, which was below the stock's 30-day daily average volume of 3.83 million. Over the last one month, the stock of Teva declined by 3.54%, compared to the Dow Jones Industrial Average which fell 1.06% during the same period. The full research reports on Teva are available to download free of charge at:
Pharmacyclics Inc. Research Reports
On August 18, 2014, Pharmacyclics Inc. (Pharmacyclics) announced the appointment of Shawn Cline Tomasello as its Chief Commercial Officer. Pharmacyclics informed that Cline Tomasello brings 30 years of experience spanning across companies like Celgene Corporation, Genentech, Pfizer Laboratories, Miles Pharmaceuticals and Proctor & Gamble. Most recently, Cline Tomasello was the President of the Americas, Hematology and Oncology for the Celgene Corporation, where she managed over $4 billion in revenue. "We are delighted to welcome Shawn in this important position. Her exceptional and proven leadership skills and depth of experience within the hematology-oncology space will be tremendously valuable to the ongoing success and growth of IMBRUVICA® and to our company," said Bob Duggan, Chairman and CEO, Pharmacyclics. The full research reports on Pharmacyclics are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
Feb. 26, 2017 05:00 AM EST Reads: 4,827
Feb. 26, 2017 03:45 AM EST Reads: 8,490
Feb. 26, 2017 03:15 AM EST Reads: 2,016
Feb. 26, 2017 03:00 AM EST Reads: 2,752
Feb. 26, 2017 02:30 AM EST Reads: 13,718
Feb. 26, 2017 02:30 AM EST Reads: 2,335
Feb. 26, 2017 02:00 AM EST Reads: 4,775
Feb. 26, 2017 01:45 AM EST Reads: 6,216
Feb. 26, 2017 01:30 AM EST Reads: 5,219
Feb. 26, 2017 01:15 AM EST Reads: 1,742
Feb. 26, 2017 12:00 AM EST Reads: 1,497
Feb. 25, 2017 10:45 PM EST Reads: 8,593
Feb. 25, 2017 10:30 PM EST Reads: 1,871
Feb. 25, 2017 09:45 PM EST Reads: 9,327
Feb. 25, 2017 09:00 PM EST Reads: 9,134